Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Combination therapy for sarcoidosis.

R P Baughman1, M Ohmichi, E E Lower

  • 1Department of Medicine, University of Cincinnati Medical Center, 231 Albert Sabin Way, Room 6004, Cincinnati, OH 45267-0564, USA. bob.baughman@uc.edu

Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG
|July 5, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The St. George's Respiratory Questionnaire in Pulmonary Sarcoidosis.

Lung·2020
Same author

Vascular branches from cutaneous nerve of the forearm and hand: Application to better understanding raynaud's disease.

Clinical anatomy (New York, N.Y.)·2017
Same author

Measuring sarcoidosis around the world: Using the same ruler.

Revista portuguesa de pneumologia·2017
Same author

Idiopathic granulomatous mastitis: A diagnostic and therapeutic challenge.

American journal of surgery·2017
Same author

Sarcoidosis extent relates to molecular variability.

Clinical and experimental immunology·2017
Same author

Tadalafil therapy for sarcoidosis-associated pulmonary hypertension.

Pulmonary circulation·2017
Same journal

Clinical remission in elderly patients with sarcoidosis.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG·2026
Same journal

A case of a rapidly progressing, recurrent orbital mass.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG·2026
Same journal

Composite Inflammatory Indices for the Differentiation of Tuberculosis, Sarcoidosis, and Reactive Lymphadenopathy in Patients Undergoing EBUS-TBNA.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG·2026
Same journal

Supervised Home-Based Telerehabilitation for Idiopathic Pulmonary Fibrosis: A Pragmatic Service Evaluation in Routine Care with Detraining Follow-up.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG·2026
Same journal

Transcriptomic profiling of collagen gene expression in lung fibroblasts from patients with idiopathic pulmonary fibrosis.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG·2026
Same journal

Unveiling novel susceptibility genes for sarcoidosis by a cross-tissue transcriptome-wide association study.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG·2026
See all related articles

Combination therapy is increasingly used for sarcoidosis, combining agents like corticosteroids, cytotoxic drugs, and immune modifiers to potentially improve treatment efficacy and reduce toxicity.

Area of Science:

  • Immunology
  • Pharmacology
  • Internal Medicine

Background:

  • Combination therapy is established in various diseases.
  • Its role in sarcoidosis treatment is not well-defined.
  • Current sarcoidosis treatment involves stepwise approaches with corticosteroids.

Purpose of the Study:

  • To explore the role and rationale of combination therapy in sarcoidosis.
  • To discuss the combination of cytotoxic agents with corticosteroids.
  • To examine the use of cytotoxic and immune modifiers for refractory sarcoidosis.

Main Methods:

  • Literature review of combination therapy in sarcoidosis.
  • Analysis of stepwise treatment approaches.
  • Examination of drug combinations including corticosteroids, cytotoxic agents, and immune modifiers.

Related Experiment Videos

Main Results:

  • Combination therapy is being explored for sarcoidosis.
  • Cytotoxic agents are combined with corticosteroids.
  • Refractory cases utilize combinations of cytotoxic and immune-modifying drugs.

Conclusions:

  • Combination therapy in sarcoidosis may enhance treatment efficacy.
  • Combining agents may allow for reduced corticosteroid doses.
  • This approach holds potential for reduced overall toxicity in sarcoidosis management.